Literature DB >> 19549278

The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan.

Tomonori Hidaka1, Kotaro Shide, Haruko Shimoda, Takurou Kameda, Keiko Toyama, Keiko Katayose, Youko Kubuki, Kenji Nagata, Katsuto Takenaka, Koichi Akashi, Takashi Okamura, Yoshiyuki Niho, Hideaki Mizoguchi, Mitsuhiro Omine, Keiya Ozawa, Mine Harada, Kazuya Shimoda.   

Abstract

Cytogenetic abnormalities were often observed in primary myelofibrosis patients. The presence of specific cytogenetic abnormalities, such as sole abnormalities of chromosome 13q-, 20q-, or -7/7q-, is reported to have the influence on the prognosis of primary myelofibrosis. We analyzed the data from the prospective survey of Japanese primary myelofibrosis patients which was conducted from 1999 to clarify the impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis. A total of 202 primary myelofibrosis patients had the cytogenetic and the prognostic data. Eighty (40%) out of 202 cases had cytogenetic abnormalities, and an association was evident for platelet counts. Although the presence of an abnormal karyotype did not affect the prognosis, primary myelofibrosis patients with cytogenetic abnormalities other than 13q- and 20q- showed an inferior prognosis compared to patients with a normal karyotype or sole 13q- or 20q- abnormalities. Patients with an unfavorable cytogenetic profile (abnormal cytogenetics other than 13q- or 20q-) also had a greater tendency to transform to leukemia than patients with a favorable cytogenetic profile (normal cytogenetics, sole abnormalities of either chromosome 13q-, or 20q-). Abnormal cytogenetics other than 13q- or 20q- in primary myelofibrosis patients has the poor prognostic effect for both survival and the risk of leukemic transformation.

Entities:  

Mesh:

Year:  2009        PMID: 19549278     DOI: 10.1111/j.1600-0609.2009.01298.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  7 in total

1.  Prognostication in primary myelofibrosis.

Authors:  Francisco Cervantes; Arturo Pereira
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

2.  Clinical features and outcomes of patients with primary myelofibrosis in Japan: report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan.

Authors:  Katsuto Takenaka; Kazuya Shimoda; Naoyuki Uchida; Taizo Shimomura; Koji Nagafuji; Tadakazu Kondo; Hirohiko Shibayama; Takehiko Mori; Kensuke Usuki; Taichi Azuma; Yutaka Tsutsumi; Junji Tanaka; Hitomi Dairaku; Keitaro Matsuo; Keiya Ozawa; Mineo Kurokawa; Shunya Arai; Koichi Akashi
Journal:  Int J Hematol       Date:  2016-10-19       Impact factor: 2.490

3.  Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics.

Authors:  Vincent T Ma; Philip S Boonstra; Kamal Menghrajani; Cecelia Perkins; Krisstina L Gowin; Ruben A Mesa; Jason R Gotlib; Moshe Talpaz
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2018-03-02

Review 4.  Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors.

Authors:  Vikas Gupta; Parameswaran Hari; Ronald Hoffman
Journal:  Blood       Date:  2012-06-14       Impact factor: 22.113

5.  Chromosome 5q deletion is extremely rare in patients with myelofibrosis.

Authors:  Koichi Takahashi; Jorge Cortes; Sherry Pierce; Lynne Abruzzo; Hagop Kantarjian; Srdan Verstovsek
Journal:  Leuk Res       Date:  2013-02-04       Impact factor: 3.156

6.  Emerging therapeutic options for myelofibrosis: a Canadian perspective.

Authors:  Vikas Gupta; Lynda Foltz; Shireen Sirhan; Lambert Busque; A Robert Turner
Journal:  Am J Blood Res       Date:  2012-09-23

7.  Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients.

Authors:  D Caramazza; K H Begna; N Gangat; R Vaidya; S Siragusa; D L Van Dyke; C Hanson; A Pardanani; A Tefferi
Journal:  Leukemia       Date:  2010-10-14       Impact factor: 11.528

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.